Efficacy and safety of novel NK-1 antagonist, Fosaprepitant for the prevention of CINV.
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2015
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 01 May 2012 Status changed from not yet recruiting to recruiting.
- 03 Mar 2012 New trial record